EUVIMEDSkopri EUVIMED
Open access · CC BY-NC-ND 4.0

Suzetrigine as a novel treatment for headache disorders: A case series

Molly Fensterwald, Jordan Johnson, Angel Moreno, Shawn Conger-Love, Charles Flippen, Chelsea Hesterman, Mollie Johnston, Joshua Kamins, Karla Minota, Peony Pak, Salman Hashim, Thanh-Liem Huynh-Tran and 4 more

Headache: The Journal of Head and Face Pain · 2026-07 · 66 (7) · 1644-1649

DOI: 10.1111/head.70147 ↗

At a glance

Journal article in Headache: The Journal of Head and Face Pain, published online on 2026-06-05. Written by Molly Fensterwald and 15 co-authors. Institution: Department of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA. Major MEDLINE topics: Headache Disorders. Cited 1 times so far (Crossref); 11 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Wendy and Leonard Goldberg Endowment, NCATS NIH HHS.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Suzetrigine is a selective voltage‐gated sodium channel blocker that was recently approved by the US Food and Drug Administration for the treatment of acute pain. We retrospectively evaluated the efficacy and tolerability of suzetrigine for the treatment of different headache disorders in patients refractory to standard treatments in an academic headache center. These patients had a variety of headache and facial pain diagnoses, including chronic migraine, medication‐overuse headache, trigeminal autonomic cephalalgias, nummular headache, occipital neuralgia, and persistent idiopathic facial pain. Some did not clearly meet any diagnostic criteria. The treatment was generally well tolerated, and most patients reported improvement as measured by patient global impression of change. Suzetrigine is a promising new therapeutic approach that warrants further study for the treatment of headache disorders.

Subjects

MeSH terms (MEDLINE)

Headache DisordersHumansFemaleMaleMiddle AgedAdultRetrospective StudiesTreatment OutcomeAgedAmidesAminopyridinesFurans

Author keywords

refractory headachesuzetriginetreatment

Substances

suzetrigineAmidesAminopyridinesFurans

Authors and institutions

  • Department of Neurology, Goldberg Migraine Program, University of California Los Angeles, Los Angeles, California, USA.

Funding

  • Wendy and Leonard Goldberg Endowment
  • NCATS NIH HHS

Cite

APA

Fensterwald, M., Johnson, J., Moreno, A., Conger-Love, S., Flippen, C., Hesterman, C., Johnston, M., Kamins, J., Minota, K., Pak, P., Hashim, S., Huynh-Tran, T. L., Kobayashi, N., Shane, B., Charles, A., & Nwaobi, S. (2026). Suzetrigine as a novel treatment for headache disorders: A case series. Headache: The Journal of Head and Face Pain, 66(7), 1644-1649. https://doi.org/10.1111/head.70147

Vancouver

Fensterwald M, Johnson J, Moreno A, Conger-Love S, Flippen C, Hesterman C, et al. Suzetrigine as a novel treatment for headache disorders: A case series. Headache: The Journal of Head and Face Pain. 2026;66(7):1644-1649. doi:10.1111/head.70147

BibTeX
@article{Fensterwald2026,
  author = {Fensterwald, Molly and Johnson, Jordan and Moreno, Angel and Conger-Love, Shawn and Flippen, Charles and Hesterman, Chelsea and Johnston, Mollie and Kamins, Joshua and Minota, Karla and Pak, Peony and Hashim, Salman and Huynh-Tran, Thanh-Liem and Kobayashi, Noelle and Shane, Bradley and Charles, Andrew and Nwaobi, Sinifunanya},
  title = {Suzetrigine as a novel treatment for headache disorders: A case series},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2026},
  volume = {66},
  number = {7},
  pages = {1644--1649},
  doi = {10.1111/head.70147}
}
Start for free →